MARKET

KPTI

KPTI

Karyopharm Therapeutics Inc
NASDAQ
5.57
+0.27
+5.09%
After Hours: 5.57 0 0.00% 18:48 03/31 EDT
OPEN
5.31
PREV CLOSE
5.30
HIGH
5.75
LOW
5.31
VOLUME
505.54K
TURNOVER
--
52 WEEK HIGH
10.99
52 WEEK LOW
3.510
MARKET CAP
125.57M
P/E (TTM)
-0.3107
1D
5D
1M
3M
1Y
5Y
1D
Karyopharm Therapeutics Price Target Cut to $8.00/Share From $12.00 by Piper Sandler
Dow Jones · 1d ago
Piper Sandler Reiterates Overweight on Karyopharm Therapeutics, Lowers Price Target to $8
Benzinga · 1d ago
Piper Sandler Releases a Buy Rating on Karyopharm Therapeutics (KPTI)
TipRanks · 1d ago
Karyopharm price target lowered to $8 from $12 at Piper Sandler
TipRanks · 1d ago
Weekly Report: what happened at KPTI last week (0323-0327)?
Weekly Report · 2d ago
U.S. RESEARCH ROUNDUP- Ferguson Enterprises, Hartford Insurance Group, JP Morgan
Reuters · 2d ago
KARYOPHARM THERAPEUTICS INC <KPTI.O>: PIPER SANDLER CUTS TARGET PRICE TO $8 FROM $12
Reuters · 2d ago
Karyopharm Strengthens Liquidity With New Equity Financing
TipRanks · 4d ago
More
About KPTI
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer. It is developing and commercializing novel, small molecule XPO1 inhibitor compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. XPOVIO is also marketed for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including myelofibrosis, endometrial cancer and multiple myeloma. The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.

Webull offers Karyopharm Therapeutics Inc stock information, including NASDAQ: KPTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KPTI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KPTI stock methods without spending real money on the virtual paper trading platform.